Colorectal Cancer Alliance announces funding recipients for colon and rectal cancer research needs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Colorectal Cancer Alliance is providing a total of $625,000 in grants to four researchers, including one advancing personalized treatment options for rectal cancer patients and three seeking to understand the root cause of rising colorectal cancer rates in patients under age 50.

Grant recipients include:

  • J. Joshua Smith of Memorial Sloan Kettering Cancer Center who will build on his previous research using patient-specific rectal cancer organoids to grow human-specific rectal cancer models in mice as a platform for developing personalized treatments.

  • Robin B. Mendelson of Memorial Sloan Kettering Cancer Center who will describe the gut microbiome of patients under age of 50, comparing them to the microbiomes of older people with colorectal cancer and the microbiomes of younger healthy people.

  • Joshua Meyer of Fox Chase Cancer Center who will describe the genetic and genomic features of colorectal cancer patients young and old, and thoroughly characterize the biology of young-onset colorectal in patients under 50 years old.

  • Rosa Maria Munoz Xicola of the Yale School of Medicine will provide essential knowledge on how the APC-negative subset of colorectal cancers develop, which is crucial in the development of effective early detection tests and treatments. Xicola will also investigate whether the APC-negative subset disproportionately affects African Americans and young people.

The Colorectal Cancer Alliance is now accepting applications for its prevention research grants. The application deadline is 11:59 p.m., Monday, March 18, 2019.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login